ERYtech Pharma Starts its Pivotal Clinical Trial for GRASPA(R) in Acute Lymphoblastic Leukaemia

LYON, France & PHILADELPHIA--(BUSINESS WIRE)--ERYtech Pharma announces the start of its pivotal clinical trial for GRASPA®, its lead product in Acute Lymphoblastic Leukaemia. This phase III trial has begun in France and will be enlarged to a European scale. Up to 80 patients with relapsed Acute Lymphoblastic Leukaemia, aged from 1 to 55 years old will be enrolled. The endpoint combines safety and efficacy with regard to the asparagine depletion level.